DNLI | tickerfilter.com

Fundamental analysis

24%

Profitability 0%

Dept financing 27%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.82%

1 Month

-2.61%

3 Months

10.43%

6 Months

21.11%

1 Year

56.20%

2 Year

28.46%

Key data

Stock price

$20.54

P/E Ratio

0.00

DAY RANGE

$20.09 - $20.88

EPS

-$2.97

52 WEEK RANGE

$12.58 - $23.77

52 WEEK CHANGE

$40.68

MARKET CAP

2.421 B

YIELD

N/A

SHARES OUTSTANDING

158.591 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-31-2025

BETA

2.16

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,247,424

AVERAGE 30 VOLUME

$1,842,246

Company detail

CEO: Ryan J. Watts
Region: US
Website: denalitherapeutics.com
Employees: 430
IPO year: 2017

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Denali Therapeutics Inc. discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate product candidate. BIIB122/DNL151, a small molecule inhibitor, is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

DNLI - Denali Therapeutics Inc.